Urinary Tract Infection Treatment Market

Urinary Tract Infection Treatment Market (Disease: Uncomplicated UTI and Complicated UTI; Drug Class: Quinolones, Beta-lactams, Macrolides, Aminoglycosides, and Others; Pathogen: E. coli, Pseudomonas aeruginosa, Enterococcus spp, K. pneumonia, S. aureus, and Others; Source of Infection: Hospital-acquired UTI and Community-acquired UTI; Gender: Female and Male; Distribution Channel: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

Antibiotic Stewardship Policies Tackle Growing Incidences of Antibiotic Resistance in cUTI Patients

Urinary tract infection (UTI) is one of the most prevalent health issues in most people. UTI is more common in women as compared to men, as women face health complications such as menopause, pregnancy, and certain side effects of birth control measures. However, on a global level, the urinary tract infection treatment market is challenged, as individuals are hesitant to consult doctors and healthcare providers for appropriate diagnosis.

Ongoing research and development activities in the urinary tract infection treatment market suggest the predictive factors of multidrug-resistant gram-negative bacteria in hospitalized patients suffering from complicated urinary tract infection (cUTI). Stakeholders are using the mixed-effects logistic regression model to study the symptoms in patients. Results show that, the antibiotic resistance for gram-negative bacteria is high in patients suffering from cUTI. Thus, appropriate diagnosis with healthcare providers and active enforcement of antibiotic stewardship policies will reduce the incidences of multi-drug antibiotic abstinence in patients for the treatment for complicated urinary tract infection.

urinary tract infection treatment market infographic

To know the scope of our report Get a Sample on Urinary Tract Infection Treatment Market

Market Players to Increase Awareness about Statutory Usage of Catheters

Patients with renal diseases are more susceptible to the risk of being exposed to urinary tract infection, due to long stays in the hospital, non-sanitized urinary catheters, and manipulations caused during urological treatment. As a result, healthcare providers in the urinary tract infection treatment market need to broaden the monitoring measures for patients, post-hospitalization, to reduce the incidences of urinary tract infection. Market players can create awareness in patients to carefully use urinary catheters and avoid unnecessary catheterization in patients.

On the other hand, healthcare providers are encountering increased incidences of community-acquired urinary tract infection caused by the escherichia coli (E. Coli) pathogen due to antibiotic resistance in patients. Thus, stakeholders in the urinary tract infection treatment market must cater to the growing need for effective antibiotic medication for UTI caused due to the E. Coli pathogen.

Get a glimpse of the in-depth analysis through our Report Brochure

Smartphone Apps and Instant Urine Cultures Serve as Cost-effective Remedies in UTI Treatment

Stakeholders in the UTI treatment market are developing new smartphone apps designed for women. These apps are created by on-boarding several doctors and pharmacies. With the growing influx of digitization in the healthcare industry, stakeholders can eliminate the issue of long-queue appointments with general practitioners for individuals. With effective diagnosis from doctors through the app, doctors can prescribe the right medication for the treatment of urinary tract infection, and pharmacists can supply home-testing kits and other medicinal antibiotics on demand. This digitization phenomena has created a win-win situation for stakeholders and healthcare providers, as well as pharmacists.

One of the biggest challenges that stakeholders operating in the urinary tract infection treatment market are facing is the antibiotic resistance for the treatment of urinary tract infection, even in healthy individuals with strong immune systems. As such, they are tackling the issue of antibiotic resistance with high-end antibiotics. Players operating in the urinary tract infection treatment market are also developing cost-effective solutions such as instant urine cultures to assess the resistance levels of individuals for antibiotics. For instance, in November 2018, Allergan — a leading pharmaceutical company, announced the launch of the FDA accepted supplemental drug ? AVYCAZ, for the treatment of complicated urinary tract infections (cUTI) and complicated intra-abdominal infections, for patients between the age group of 3 months to 18 years.

urinary tract infection treatment market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report 

Analysts’ Viewpoint on the UTI Treatment Market

Analysts of the urinary tract infection treatment market portray a promising future for stakeholders during the forecast period of 2019-2027. Market players need to focus on innovating treatment options for urinary tract infection catering to complicated urinary tract infection, as currently cUTI accounts for ~82% of the market value share. Manufacturers in the UTI treatment market can build strategic tie-ups with hospital pharmacists, as they dominate the market value share, amounting to ~47%, though, retail pharmacists will have high growth potential in the coming years. Market players are challenged with high antibiotic resistance in UTI patients. This challenge can be overcome with increased offerings for at-home instant urine culture tests and the development of smartphone apps.

  • According to Transparency Market Research’s latest report on the global urinary tract infection treatment market for the historical period of 2017–2018 and forecast period of 2019-2027, rise in the awareness about urinary tract infection among women and increase in the adoption of new diagnostic tests are projected to boost the growth of the global urinary tract infection treatment market.
  • According to the report, the global urinary tract infection treatment market was valued at ~US$ 5.9 Bn in 2018 and is anticipated to expand at a CAGR of ~3% from 2019 to 2027.

Rise in Prevalence of Urinary Tract Infection (UTI): A Key Driver

  • Urinary tract infection (UTI) is one of the chronic diseases associated with the bladder, urethra, ureter, and kidneys. Over-reliance and high consumption of antibiotics are likely to increase antibiotic resistance in most UTI causing pathogens. This is projected to increase the prevalence of UTI in the near future.
  • According to the Pharmacotherapy Self-Assessment Program: Hematology/Oncology, in the U.S., around 60% women have symptomatic UTI during their lifetime, and around 10% women have one or more than one UTI episodes each year.
  • According to the National Institute for Health Research, an estimated 92 million people contracted urinary tract infection across the globe in 2013.
  • Most urinary tract infections are caused due to the presence of E. coli. According to a study published in the International Journal of Contemporary Medical Research, approximately 37.4% of UTIs were caused due to E. coli during 2016–2017.

Development of New Antibiotics and Advancements in Diagnosis of UTI

  • Key market players in the urinary tract infection treatment market focus on the development of new antibiotics for the treatment of urinary tract infections. In July 2019, the U.S. Food and Drug Administration approved the antibacterial drug – Recarbrio - for the treatment of complicated UTI and complicated intra-abdominal infection in adults.
  • In June 2018, Achaogen, Inc. received the U.S. Food and Drug Administration approval for ZEMDRI, for the treatment of complicated urinary tract infection in adults.
  • Biosensor is an advanced platform for the diagnosis of urinary tract infection. Biosensors can be integrated with microfluidic technology for point-of-care applications to improve UTI diagnosis.
  • New assays such as flow cytometry, MALDI-TOF mass spectrometry, fluorescence in situ hybridization, and multiplex PCR also help improve the diagnosis of urinary tract infections.

Introduction of Generic Drugs Restrains Market

  • The launch of new generic products in the market is a major factor hampering the growth of the global urinary tract infection treatment market.
  • In June 2018, Aurobindo Pharma received the U.S. Food and Drug Administration approval for the manufacturing and marketing of the generic Entrapenem injection. It is a generic version of Invanz offered by Merck Sharp & Dohme Corp.
  • In July 2018, Lupin received approval from the U.S. Food and Drug Administration for generic Nitrofurantoin Capsules. It is a generic version of Macrodantin offered by Alvogen Malta Operations Ltd. It is used in the treatment of UTI that occurs due to Staphylococcus aureus, enterococci, and others.

Global Urinary Tract Infection Treatment Market: Competitive Landscape

  • This report profiles major players in the global urinary tract infection treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments.
  • The urinary tract infection treatment market is moderately fragmented, with the presence of a few large-scale players present in international markets and numerous small-scale players in regional markets. The top 4 to 5 players hold a majority share of the global urinary tract infection treatment market.

Prominent players operating in the urinary tract infection treatment market include

  • Allergan
  • Bayer AG
  • Pfizer, Inc.
  • GlaxoSmithKline plc
  • Bristol-Myers Squibb Company
  • Janssen Global Services, LLC
  • Lupin Ltd.
  • Merck & Co., Inc
  • (Merck Sharp & Dohme Corp)
  • Dr. Reddy’s Laboratories Ltd.
  • ​Almirall, S.A

Global Urinary Tract Infection Treatment Market: Key Developments

Key players in the global urinary tract infection treatment market engage in new product development and approvals, key mergers & acquisitions, and collaborations. These strategies by industry players are likely to augment the global urinary tract infection treatment market. Some developments in the global urinary tract infection treatment market are as follows:

  • In March 2019, Allergan received the U.S. Food and Drug Administration approval for the supplemental New Drug Application for AVYCAZ to expand the label to include pediatric patients three months and older, for the treatment of complicated urinary tract infection (cUTI) and complicated intra-abdominal infections (cIAI). This is the first FDA approval for cUTI and cIAI for pediatric patients.
  • In August 2016, Pfizer, Inc. entered into an agreement with AstraZeneca to acquire the development and commercialization rights to its anti-infectives business. This acquisition enabled the company to expand and broaden its access to the anti-infective product portfolio. Moreover, the acquisition strengthened Pfizer, Inc.’s essential health business segment.
  • In October 2016, Fimbrion Therapeutics, Inc. and GlaxoSmithKline plc entered into a collaboration to develop a small molecule drug for the treatment and prevention of urinary tract infection.

In the global urinary tract infection treatment market report, we have discussed individual strategies, followed by company profiles of the manufacturers of urinary tract infection products. The ‘Competitive Landscape’ section is included in the market report to provide readers with a dashboard view and a company market share analysis of the key players operating in the global urinary tract infection treatment market.

Urinary Tract Infection Treatment Market - Segmentation

The comprehensive study on the urinary tract infection treatment market provides a comprehensive analysis of the market attractiveness by offering insights into the key segments. The urinary tract infection treatment market has been segregated on the basis of disease, drug class, pathogen, source of infection, gender, distribution channel, and region. The global study highlights a country-wise analysis to lend incisive insights about the healthcare innovations of urinary tract infection treatments.

Each of the segments included in this report help in gaining crucial insights into the urinary tract infection treatment market. The study on the urinary tract infection treatment market offers historical, current, and futuristic trends influencing its growth. In addition to this, it covers value chain analysis, Y-o-Y growth analysis, and supply chain analysis.

Disease

Uncomplicated UTI

Complicated UTI

Drug Class

Quinolones

Beta-lactams

Macrolides

Aminoglycosides

Others

Pathogen

E. Coli

Pseudomonas aeruginosa

Enterococcus spp

K. pneumoniae

S. aureus

Others

Source of Infection

Hospital-acquired UTI

Community-acquired UTI

Gender

Female

Male

Distribution Channel

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

 

Frequently Asked Questions

How big was the global urinary tract infection treatment market in 2018?

The urinary tract infection treatment market was valued at ~US$ 5.9 Bn in 2018

What is the total market worth of urinary tract infection treatment market?

Urinary tract infection treatment market is expected to touch US$ 7.5 Bn in 2027

What is the anticipated CAGR of the urinary tract infection treatment market in the forecast period?

Urinary tract infection treatment market to expand at a CAGR of ~3% from 2019 to 2027

What are the key driving factors for the growth of the urinary tract infection treatment market?

Urinary tract infection treatment market is driven by rise in the awareness about urinary tract infection among women

Who are the key players in the urinary tract infection treatment market?

Key players in the urinary tract infection treatment market include Allergan, Bayer AG, Pfizer, Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Urinary Tract Infection Treatment Market

    4. Market Overview

        4.1. Introduction

              4.1.1. Disease Definition

              4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

              4.3.1. Drivers

                          4.3.1.1 Rise in prevalence of UTI

                          4.3.1.2. Increase in number of hospital acquired infection

                          4.3.1.3. Rise in awareness about women's health

                          4.3.1.4. Introduction of new diagnostic test

                          4.3.1.5. Development of new antibiotics

              4.3.2. Restraints

                          4.3.2.1 Introduction of generic drug

                          4.3.2.2. Patent Expiry

              4.3.3. Opportunities

        4.4. Global Urinary Tract Infection Treatment Market Analysis and Forecast, 2017–2027

    5. Market Outlook

        5.1. Epidemiology Overview of UTI by Key Countries (Prevalence, Incidence, Overall Burden)

        5.2. Pipeline Analysis

        5.3. Overview of Guidelines for Diagnosis & Treatment of UTI’s 

        5.4. Reimbursement Scenario

        5.5. Overview of Multi-Drug Resistance Pathogen and Infections (Infection Types & Prevalence, Most drug resistant Bacterial Strains)

        5.6. Advancements in UTI diagnosis (Rapid Action Tests, New Assays in Anti-microbial susceptibility testing, etc.)

    6. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Disease 

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Disease, 2017–2027

              6.3.1. Uncomplicated UTI 

              6.3.2. Complicated UTI

        6.4. Market Attractiveness, by Disease 

    7. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Drug Class 

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Drug Class, 2017–2027

              7.3.1. Quinolones

              7.3.2. Beta-lactams

              7.3.3. Macrolides

              7.3.4. Aminoglycosides

              7.3.5. Others

        7.4. Market Attractiveness, by Drug Class 

    8. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Pathogen 

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by Pathogen, 2017–2027

              8.3.1. E. coli

              8.3.2. Pseudomonas aeruginosa

              8.3.3. Enterococcus spp

              8.3.4. K. pneumoniae

              8.3.5. S. aureus

              8.3.6. Others

        8.4. Market Attractiveness, by Pathogen 

    9. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Source of Infection

        9.1. Introduction & Definition

        9.2. Key Findings / Developments

        9.3. Market Value Forecast, by Source of Infection, 2017–2027

              9.3.1. Hospital Acquired UTI

              9.3.2. Community Acquired UTI 

        9.4. Market Attractiveness, by Source of Infection

    10. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Gender 

        10.1. Introduction & Definition

        10.2. Key Findings / Developments

        10.3. Market Value Forecast, by Gender, 2017–2027

              10.3.1. Female

              10.3.2. Male

        10.4. Market Attractiveness, by Gender 

    11. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Distribution Channel 

        11.1. Introduction & Definition

        11.2. Key Findings / Developments

        11.3. Market Value Forecast, by Distribution Channel, 2017–2027

              11.3.1. Retail Pharmacies

              11.3.2. Hospital Pharmacies

              11.3.3. Online Pharmacies 

        11.4. Market Attractiveness, by Distribution Channel 

    12. Global Urinary Tract Infection Treatment Market Analysis and Forecast, by Region

        12.1. Key Findings

        12.2. Market Value Forecast, by Region

              12.2.1. North America 

              12.2.2. Europe 

              12.2.3. Asia Pacific 

              12.2.4. Latin America 

              12.2.5. Middle East & Africa 

        12.3. Market Attractiveness, by Country/Region

    13. North America Urinary Tract Infection Treatment Market Analysis and Forecast

        13.1. Introduction

              13.1.1. Key Findings

        13.2. Market Value Forecast, by Disease, 2017–2027

              13.2.1. Uncomplicated UTI 

              13.2.2. Complicated UTI

        13.3. Market Value Forecast, by Drug Class, 2017–2027

              13.3.1. Quinolones

              13.3.2. Beta-lactams

              13.3.3. Macrolides

              13.3.4. Aminoglycosides

              13.3.5. Others

        13.4. Market Value Forecast, by Pathogen, 2017–2027

              13.4.1. E. coli

              13.4.2. Pseudomonas aeruginosa

              13.4.3. Enterococcus spp

              13.4.4. K. pneumoniae

              13.4.5. S. aureus

              13.4.6. Others

        13.5. Market Value Forecast, by Source of Infection, 2017–2027

              13.5.1. Hospital Acquired UTI

              13.5.2. Community Acquired UTI 

        13.6. Market Value Forecast, by Gender, 2017–2027

              13.6.1. Female

              13.6.2. Male

        13.7. Market Value Forecast, by Distribution Channel, 2017–2027

              13.7.1. Retail Pharmacies

              13.7.2. Hospital Pharmacies

              13.7.3. Online Pharmacies 

        13.8. Market Value Forecast, by Country, 2017–2027

              13.8.1. U.S.

              13.8.2. Canada

        13.9. Market Attractiveness Analysis 

              13.9.1. By Disease 

              13.9.2. By Drug Class 

              13.9.3. By Pathogen 

              13.9.4. By Source of Infection

              13.9.5. By Gender 

              13.9.6. By Distribution Channel 

              13.9.7. By Country

    14. Europe Urinary Tract Infection Treatment Market Analysis and Forecast

        14.1. Introduction

              14.1.1. Key Findings

        14.2. Market Value Forecast, by Disease, 2017–2027

              14.2.1. Uncomplicated UTI 

              14.2.2. Complicated UTI

        14.3. Market Value Forecast, by Drug Class, 2017–2027

              14.3.1. Quinolones

              14.3.2. Beta-lactams

              14.3.3. Macrolides

              14.3.4. Aminoglycosides

              14.3.5. Others

        14.4. Market Value Forecast, by Pathogen, 2017–2027

              14.4.1. E. coli

              14.4.2. Pseudomonas aeruginosa

              14.4.3. Enterococcus spp

              14.4.4. K. pneumoniae

              14.4.5. S. aureus

              14.4.6. Others

        14.5. Market Value Forecast, by Source of Infection, 2017–2027

              14.5.1. Hospital Acquired UTI

              14.5.2. Community Acquired UTI 

        14.6. Market Value Forecast, by Gender, 2017–2027

              14.6.1. Female

              14.6.2. Male

        14.7. Market Value Forecast, by Distribution Channel, 2017–2027

              14.7.1. Retail Pharmacies

              14.7.2. Hospital Pharmacies

              14.7.3. Online Pharmacies 

        14.8. Market Value Forecast, by Country/Sub-region, 2017–2027

              14.8.1. Germany

              14.8.2. U.K.

              14.8.3. France

              14.8.4. Spain

              14.8.5. Italy

              14.8.6. Rest of Europe

        14.9. Market Attractiveness Analysis 

              14.9.1. By Disease 

              14.9.2. By Drug Class 

              14.9.3. By Pathogen 

              14.9.4. By Source of Infection

              14.9.5. By Gender 

              14.9.6. By Distribution Channel 

              14.9.7. By Country/Sub-region

    15. Asia Pacific Urinary Tract Infection Treatment Market Analysis and Forecast

        15.1. Introduction

              15.1.1. Key Findings

        15.2. Market Value Forecast, by Disease, 2017–2027

              15.2.1. Uncomplicated UTI 

              15.2.2. Complicated UTI

        15.3. Market Value Forecast, by Drug Class, 2017–2027

              15.3.1. Quinolones

              15.3.2. Beta-lactams

              15.3.3. Macrolides

              15.3.4. Aminoglycosides

              15.3.5. Others

        15.4. Market Value Forecast, by Pathogen, 2017–2027

              15.4.1. E. coli

              15.4.2. Pseudomonas aeruginosa

              15.4.3. Enterococcus spp

              15.4.4. K. pneumoniae

              15.4.5. S. aureus

              15.4.6. Others

        15.5. Market Value Forecast, by Source of Infection, 2017–2027

              15.5.1. Hospital Acquired UTI

              15.5.2. Community Acquired UTI 

        15.6. Market Value Forecast, by Gender, 2017–2027

              15.6.1. Female

              15.6.2. Male

        15.7. Market Value Forecast, by Distribution Channel, 2017–2027

              15.7.1. Retail Pharmacies

              15.7.2. Hospital Pharmacies

              15.7.3. Online Pharmacies 

        15.8. Market Value Forecast, by Country/Sub-region, 2017–2027

              15.8.1. China

              15.8.2. Japan

              15.8.3. India

              15.8.4. Australia & New Zealand

              15.8.5. Rest of Asia Pacific

        15.9. Market Attractiveness Analysis 

              15.9.1. By Disease 

              15.9.2. By Drug Class 

              15.9.3. By Pathogen 

              15.9.4. By Source of Infection

              15.9.5. By Gender 

              15.9.6. By Distribution Channel 

              15.9.7. By Country/Sub-region

    16. Latin America Urinary Tract Infection Treatment Market Analysis and Forecast

        16.1. Introduction

              16.1.1. Key Findings

        16.2. Market Value Forecast, by Disease, 2017–2027

              16.2.1. Uncomplicated UTI 

              16.2.2. Complicated UTI

        16.3. Market Value Forecast, by Drug Class, 2017–2027

              16.3.1. Quinolones

              16.3.2. Beta-lactams

              16.3.3. Macrolides

              16.3.4. Aminoglycosides

              16.3.5. Others

        16.4. Market Value Forecast, by Pathogen, 2017–2027

              16.4.1. E. coli

              16.4.2. Pseudomonas aeruginosa

              16.4.3. Enterococcus spp

              16.4.4. K. pneumoniae

              16.4.5. S. aureus

              16.4.6. Others

        16.5. Market Value Forecast, by Source of Infection, 2017–2027

              16.5.1. Hospital Acquired UTI

              16.5.2. Community Acquired UTI 

        16.6. Market Value Forecast, by Gender, 2017–2027

              16.6.1. Female

              16.6.2. Male

        16.7. Market Value Forecast, by Distribution Channel, 2017–2027

              16.7.1. Retail Pharmacies

              16.7.2. Hospital Pharmacies

              16.7.3. Online Pharmacies 

        16.8. Market Value Forecast, by Country/Sub-region, 2017–2027

              16.8.1. Brazil          

              16.8.2. Mexico

              16.8.3. Rest of Latin America

        16.9. Market Attractiveness Analysis 

              16.9.1. By Disease

              16.9.2. By Drug Class 

              16.9.3. By Pathogen 

              16.9.4. By Source of Infection

              16.9.5. By Gender 

              16.9.6. By Distribution Channel 

              16.9.7. By Country/Sub-region

    17. Middle East & Africa Urinary Tract Infection Treatment Market Analysis and Forecast

        17.1. Introduction

              17.1.1. Key Findings

        17.2. Market Value Forecast, by Disease, 2017–2027

              17.2.1. Uncomplicated UTI 

              17.2.2. Complicated UTI

        17.3. Market Value Forecast, by Drug Class, 2017–2027

              17.3.1. Quinolones

              17.3.2. Beta-lactams

              17.3.3. Macrolides

              17.3.4. Aminoglycosides

              17.3.5. Others

        17.4. Market Value Forecast, by Pathogen, 2017–2027

              17.4.1. E. coli

              17.4.2. Pseudomonas aeruginosa

              17.4.3. Enterococcus spp

              17.4.4. K. pneumoniae

              17.4.5. S. aureus

              17.4.6. Others

        17.5. Market Value Forecast, by Source of Infection, 2017–2027

              17.5.1. Hospital Acquired UTI

              17.5.2. Community Acquired UTI 

        17.6. Market Value Forecast, by Gender, 2017–2027

              17.6.1. Female

              17.6.2. Male

        17.7. Market Value Forecast, by Distribution Channel, 2017–2027

              17.7.1. Retail Pharmacies

              17.7.2. Hospital Pharmacies

              17.7.3. Online Pharmacies 

        17.8. Market Value Forecast, by Country/Sub-region, 2017–2027

              17.8.1. GCC Countries

              17.8.2. South Africa

              17.8.3. Rest of Middle East & Africa

        17.9. Market Attractiveness Analysis 

              17.9.1. By Disease 

              17.9.2. By Drug Class 

              17.9.3. By Pathogen 

              17.9.4. By Source of Infection

              17.9.5. By Gender 

              17.9.6. By Distribution Channel 

              17.9.7. By Country/Sub-region

    18. Competition Landscape

        18.1. Market Player - Competition Matrix (By Tier and Size of companies)

        18.2. Market Share Analysis/Ranking, by Company, 2018

        18.3. Company Profiles

              18.3.1. Allergan

                       18.3.1.1. Company Overview

                       18.3.1.2. Product Portfolio

                       18.3.1.3. SWOT Analysis

                       18.3.1.4. Financial Overview

                       18.3.1.5. Strategic Overview

              18.3.2. Bayer AG 

                       18.3.2.1. Company Overview

                       18.3.2.2. Product Portfolio

                       18.3.2.3. SWOT Analysis

                       18.3.2.4. Financial Overview

                       18.3.2.5. Strategic Overview

              18.3.3. Pfizer, Inc.

                       18.3.3.1. Company Overview

                       18.3.3.2. Product Portfolio

                       18.3.3.3. SWOT Analysis

                       18.3.3.4. Financial Overview

                       18.3.3.5. Strategic Overview

              18.3.4. GlaxoSmithKline plc

                       18.3.4.1. Company Overview

                       18.3.4.2. Product Portfolio

                       18.3.4.3. SWOT Analysis

                       18.3.4.4. Financial Overview

                       18.3.4.5. Strategic Overview

              18.3.5. Bristol-Myers Squibb Company

                       18.3.5.1. Company Overview

                       18.3.5.2. Product Portfolio

                       18.3.5.3. SWOT Analysis

                       18.3.5.4. Financial Overview

              18.3.6. Johnson & Johnson (Janssen Global Services, LLC)

                       18.3.6.1. Company Overview

                       18.3.6.2. Product Portfolio

                       18.3.6.3. SWOT Analysis

                       18.3.6.4. Financial Overview

                       18.3.6.5. Strategic Overview

              18.3.7. LUPIN

                       18.3.7.1. Company Overview

                       18.3.7.2. Product Portfolio                   

                       18.3.7.3. SWOT Analysis

                       18.3.7.4. Financial Overview

                       18.3.7.5. Strategic Overview

              18.3.8. Merck & Co., Inc. (Merck Sharp & Dohme Corp)

                       18.3.8.1. Company Overview

                       18.3.8.2. Product Portfolio

                       18.3.8.3. SWOT Analysis

                       18.3.8.4. Financial Overview

                       18.3.8.5. Strategic Overview

              18.3.9. Dr. Reddy’s Laboratories Ltd 

                       18.3.9.1. Company Overview

                       18.3.9.2. Product Portfolio

                       18.3.9.3. SWOT Analysis

                       18.3.9.4. Financial Overview

              18.3.10. Almirall, S.A

                       18.3.10.1. Company Overview

                       18.3.10.2. Product Portfolio

                       18.3.10.3. SWOT Analysis

                       18.3.10.4. Financial Overview

                       18.3.10.5. Strategic Overview

    List of Tables

    Table 01: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
    Table 02: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
    Table 03: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
    Table 04: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
    Table 05: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
    Table 06: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
    Table 07: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027
    Table 08: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
    Table 09: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
    Table 10: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
    Table 11: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
    Table 12: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
    Table 13: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
    Table 14: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
    Table 15: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
    Table 16: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
    Table 17: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
    Table 18: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
    Table 19: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
    Table 20: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
    Table 21: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
    Table 22: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
    Table 23: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
    Table 24: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
    Table 25: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
    Table 26: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
    Table 27: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
    Table 28: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
    Table 29: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
    Table 30: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
    Table 31: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
    Table 32: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
    Table 33: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
    Table 34: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
    Table 35: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
    Table 36: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Disease, 2017–2027
    Table 37: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
    Table 38: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Pathogen, 2017–2027
    Table 39: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Source of Infection, 2017–2027
    Table 40: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Gender, 2017–2027
    Table 41: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
    Table 42: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    List of Figures

    Figure 01: Global Urinary Tract Infection Treatment Market Value (US$ Mn) and Distribution (%), by Region, 2018 and 2027
    Figure 02: Global Urinary Tract Infection Treatment Market Value (US$ Mn), by Pathogen, 2018
    Figure 03: Market Snapshot - Top 2 Trends
    Figure 04: Market Overview
    Figure 05: Global Urinary Tract Infection Treatment Market Value Share, by Disease, 2018
    Figure 06: Global Urinary Tract Infection Treatment Market Value Share, by Drug Class, 2018
    Figure 07: Global Urinary Tract Infection Treatment Market Value Share, by Pathogen, 2018
    Figure 08: Global Urinary Tract Infection Treatment Market Value Share, by Source of Infection, 2018
    Figure 09: Global Urinary Tract Infection Treatment Market Value Share, by Gender, 2018
    Figure 10: Global Urinary Tract Infection Treatment Market Value Share, by Distribution Channel, 2018
    Figure 11: Global Urinary Tract Infection Treatment Value Share, by region, 2018
    Figure 12: Global Urinary Tract Infection Treatment Market Value Share, by Region, 2018
    Figure 13: Global Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast, 2017–2027
    Figure 14: Global Urinary Tract Infection Treatment Market Value Share Analysis, by Disease, 2018 and 2027
    Figure 15: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Uncomplicated UTI, 2017–2027
    Figure 16: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Complicated UTI, 2017–2027
    Figure 17: Global Urinary Tract Infection Treatment Market Attractiveness Analysis, by Disease, 2018–2027
    Figure 18: Global Urinary Tract Infection Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
    Figure 19: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Quinolones, 2017–2027
    Figure 20: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Beta-lactams, 2017–2027
    Figure 21: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Macrolides, 2017–2027
    Figure 22: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Aminoglycosides, 2017–2027
    Figure 22: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Others, 2017–2027
    Figure 23: Global Urinary Tract Infection Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
    Figure 24: Global Urinary Tract Infection Treatment Market Value Share Analysis, by Pathogen, 2018 and 2027
    Figure 25: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by E. Coli, 2017–2027
    Figure 26: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Pseudomonas aeruginosa, 2017–2027
    Figure 27: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Enterococcus spp, 2017–2027
    Figure 28: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by K. pneumoniae, 2017–2027
    Figure 29: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by S. aureus, 2017–2027
    Figure 30: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Others, 2017–2027
    Figure 31: Global Urinary Tract Infection Treatment Market Attractiveness Analysis, by Pathogen, 2018–2026
    Figure 32: Global Urinary Tract Infection Treatment Market Value Share Analysis, by Source of Infection, 2018 and 2027
    Figure 33: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Hospital Acquired UTI, 2017–2027
    Figure 34: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Community Acquired UTI, 2017–2027
    Figure 35: Global Urinary Tract Infection Treatment Market Attractiveness Analysis, by Source of Infection, 2018–2026
    Figure 36: Global Urinary Tract Infection Treatment Market Value Share Analysis, by Gender, 2018 and 2027
    Figure 37: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Female, 2017–2027
    Figure 38: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Male, 2017–2027
    Figure 39: Global Urinary Tract Infection Treatment Market Attractiveness Analysis, by Gender, 2018–2026
    Figure 40: Global Urinary Tract Infection Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
    Figure 41: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Retail Pharmacies, 2017–2027
    Figure 42: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Hospital Pharmacies, 2017–2027
    Figure 43: Global Urinary Tract Infection Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Retail Pharmacies, 2017–2027
    Figure 44: Global Urinary Tract Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2018–2027
    Figure 45: Global Urinary Tract Infection Treatment Market Value Share Analysis, by Region, 2018 and 2027
    Figure 46: Global Urinary Tract Infection Treatment Market Attractiveness Analysis, by Region, 2018–2026
    Figure 47: North America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
    Figure 48: North America Urinary Tract Infection Treatment Market Value Share Analysis, by Disease, 2018 and 2027
    Figure 49: North America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Disease, 2019–2027
    Figure 50: North America Urinary Tract Infection Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
    Figure 51: North America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Drug Class, 2019?2027
    Figure 52: North America Urinary Tract Infection Treatment Market Value Share Analysis, by Pathogen, 2018 and 2027
    Figure 53: North America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Pathogen, 2019?2027
    Figure 54: North America Urinary Tract Infection Treatment Market Value Share Analysis, by Source of Infection, 2018 and 2027
    Figure 55: North America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Source of Infection, 2019?2027
    Figure 56: North America Urinary Tract Infection Treatment Market Value Share Analysis, by Gender, 2018 and 2027
    Figure 57: North America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Gender, 2019?2027
    Figure 58: North America Urinary Tract Infection Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
    Figure 59: North America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2019 -2027
    Figure 60: North America Urinary Tract Infection Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
    Figure 61: North America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
    Figure 62: Europe Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
    Figure 63: Europe Urinary Tract Infection Treatment Market Value Share Analysis, by Disease, 2018 and 2027
    Figure 64: Europe Urinary Tract Infection Treatment Market Attractiveness Analysis, by Disease, 2019–2027
    Figure 65: Europe Urinary Tract Infection Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
    Figure 66: Europe Urinary Tract Infection Treatment Market Attractiveness Analysis, by Drug Class, 2019?2027
    Figure 67: Europe Urinary Tract Infection Treatment Market Value Share Analysis, by Pathogen, 2018 and 2027
    Figure 68: Europe Urinary Tract Infection Treatment Market Attractiveness Analysis, by Pathogen, 2019?2027
    Figure 69: Europe Urinary Tract Infection Treatment Market Value Share Analysis, by Source of Infection, 2018 and 2027
    Figure 70: Europe Urinary Tract Infection Treatment Market Attractiveness Analysis, by Source of Infection, 2019?2027
    Figure 71: Europe Urinary Tract Infection Treatment Market Value Share Analysis, by Gender, 2018 and 2027
    Figure 72: Europe Urinary Tract Infection Treatment Market Attractiveness Analysis, by Gender, 2019?2027
    Figure 73: Europe Urinary Tract Infection Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
    Figure 74: Europe Urinary Tract Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027
    Figure 75: Europe Urinary Tract Infection Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
    Figure 76: Europe Urinary Tract Infection Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
    Figure 77: Asia Pacific Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
    Figure 78: Asia Pacific Urinary Tract Infection Treatment Market Value Share Analysis, by Disease, 2018 and 2027
    Figure 79: Asia Pacific Urinary Tract Infection Treatment Market Attractiveness Analysis, by Disease, 2019–2027
    Figure 80: Asia Pacific Urinary Tract Infection Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
    Figure 81: Asia Pacific Urinary Tract Infection Treatment Market Attractiveness Analysis, by Drug Class, 2019?2027
    Figure 82: Asia Pacific Urinary Tract Infection Treatment Market Value Share Analysis, by Pathogen, 2018 and 2027
    Figure 83: Asia Pacific Urinary Tract Infection Treatment Market Attractiveness Analysis, by Pathogen, 2019?2027
    Figure 84: Asia Pacific Urinary Tract Infection Treatment Market Value Share Analysis, by Source of Infection, 2018 and 2027
    Figure 85: Asia Pacific Urinary Tract Infection Treatment Market Attractiveness Analysis, by Source of Infection, 2019?2027
    Figure 86: Asia Pacific Urinary Tract Infection Treatment Market Value Share Analysis, by Gender, 2018 and 2027
    Figure 87: Asia Pacific Urinary Tract Infection Treatment Market Attractiveness Analysis, by Gender, 2019?2027
    Figure 88: Asia Pacific Urinary Tract Infection Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
    Figure 89: Asia Pacific Urinary Tract Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2019 -2027
    Figure 90: Asia Pacific Urinary Tract Infection Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
    Figure 91: Asia Pacific Urinary Tract Infection Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
    Figure 92: Latin America Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
    Figure 93: Latin America Urinary Tract Infection Treatment Market Value Share Analysis, by Disease, 2018 and 2027
    Figure 94: Latin America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Disease, 2019–2027
    Figure 95: Latin America Urinary Tract Infection Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
    Figure 96: Latin America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Drug Class, 2019?2027
    Figure 97: Latin America Urinary Tract Infection Treatment Market Value Share Analysis, by Pathogen, 2018 and 2027
    Figure 98: Latin America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Pathogen, 2019?2027
    Figure 99: Latin America Urinary Tract Infection Treatment Market Value Share Analysis, by Source of Infection, 2018 and 2027
    Figure 100: Latin America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Source of Infection, 2019?2027
    Figure 101: Latin America Urinary Tract Infection Treatment Market Value Share Analysis, by Gender, 2018 and 2027
    Figure 102: Latin America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Gender, 2019?2027
    Figure 103: Latin America Urinary Tract Infection Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
    Figure 104: Latin America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027
    Figure 105: Latin America Urinary Tract Infection Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
    Figure 106: Latin America Urinary Tract Infection Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
    Figure 107: Middle East & Africa Urinary Tract Infection Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
    Figure 108: Middle East & Africa Urinary Tract Infection Treatment Market Value Share Analysis, by Disease, 2018 and 2027
    Figure 109: Middle East & Africa Urinary Tract Infection Treatment Market Attractiveness Analysis, by Disease, 2019–2027
    Figure 110: Middle East & Africa Urinary Tract Infection Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
    Figure 111: Middle East & Africa Urinary Tract Infection Treatment Market Attractiveness Analysis, by Drug Class, 2019?2027
    Figure 112: Middle East & Africa Urinary Tract Infection Treatment Market Value Share Analysis, by Pathogen, 2018 and 2027
    Figure 113: Middle East & Africa Urinary Tract Infection Treatment Market Attractiveness Analysis, by Pathogen, 2019?2027
    Figure 115: Middle East & Africa Urinary Tract Infection Treatment Market Value Share Analysis, by Source of Infection, 2018 and 2027
    Figure 116: Middle East & Africa Urinary Tract Infection Treatment Market Attractiveness Analysis, by Source of Infection, 2019?2027
    Figure 117: Middle East & Africa Urinary Tract Infection Treatment Market Value Share Analysis, by Gender, 2018 and 2027
    Figure 118: Middle East & Africa Urinary Tract Infection Treatment Market Attractiveness Analysis, by Gender, 2019?2027
    Figure 119: Middle East & Africa Urinary Tract Infection Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027
    Figure 120: Middle East & Africa Urinary Tract Infection Treatment Market Attractiveness Analysis, by Distribution Channel, 2019–2027
    Figure 121: Middle East & Africa Urinary Tract Infection Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
    Figure 122: Middle East & Africa Urinary Tract Infection Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
    Figure 123: Global Urinary Tract Infection Treatment Market Analysis, by Top Company Ranking, 2018
    Figure 124: Global Urinary Tract Infection Treatment Market Share, by Company, 2017 

Copyright © Transparency Market Research, Inc. All Rights reserved